Open Access
Evaluation of the Antiviral Potential of Modified Heterocyclic Base and 5’-Norcarbocyclic Nucleoside Analogs Against SARS-CoV-2
Publication type: Journal Article
Publication date: 2021-01-01
scimago Q2
wos Q4
SJR: 0.633
CiteScore: 3.4
Impact factor: 2.0
ISSN: 20758251, 20758243
PubMed ID:
35127150
Abstract
The pandemic caused by the novel betacoronavirus SARS-CoV-2 has already claimed more than 3.5 million lives. Despite the development and use of anti-COVID-19 vaccines, the disease remains a major public health challenge throughout the world. Large-scale screening of the drugs already approved for the treatment of other viral, bacterial, and parasitic infections, as well as autoimmune, oncological, and other diseases is currently underway as part of their repurposing for development of effective therapeutic agents against SARS-CoV-2. In this work, we present the results of a phenotypic screening of libraries of modified heterocyclic bases and 5’-norcarbocyclic nucleoside analogs previously synthesized by us. We identified two leading compounds with apparent potential to inhibit SARS-CoV-2 replication and EC50 values in a range of 20–70 μM. The structures of these compounds can be further optimized to develop an antiviral drug.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
International Journal of Molecular Sciences
2 publications, 40%
|
|
|
Molecular Biology
1 publication, 20%
|
|
|
Mendeleev Communications
1 publication, 20%
|
|
|
Biochemistry (Moscow)
1 publication, 20%
|
|
|
1
2
|
Publishers
|
1
2
|
|
|
Pleiades Publishing
2 publications, 40%
|
|
|
MDPI
2 publications, 40%
|
|
|
Elsevier
1 publication, 20%
|
|
|
1
2
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
5
Total citations:
5
Citations from 2024:
1
(20%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Kozlovskaya L. I. et al. Evaluation of the Antiviral Potential of Modified Heterocyclic Base and 5’-Norcarbocyclic Nucleoside Analogs Against SARS-CoV-2 // Acta Naturae. 2021. Vol. 13. No. 4. pp. 78-81.
GOST all authors (up to 50)
Copy
Matyugina E. S., Kozlovskaya L. I., Volok V. P., Shustova E. Y., Ishmukhametov A. A., Kochetkov S. N., Khandazhinskaya A., Novikov M. S. Evaluation of the Antiviral Potential of Modified Heterocyclic Base and 5’-Norcarbocyclic Nucleoside Analogs Against SARS-CoV-2 // Acta Naturae. 2021. Vol. 13. No. 4. pp. 78-81.
Cite this
RIS
Copy
TY - JOUR
DO - 10.32607/actanaturae.11479
UR - https://doi.org/10.32607/actanaturae.11479
TI - Evaluation of the Antiviral Potential of Modified Heterocyclic Base and 5’-Norcarbocyclic Nucleoside Analogs Against SARS-CoV-2
T2 - Acta Naturae
AU - Matyugina, Elena S
AU - Kozlovskaya, Liubov I.
AU - Volok, Victor P
AU - Shustova, Elena Y
AU - Ishmukhametov, Aidar A
AU - Kochetkov, Sergey N.
AU - Khandazhinskaya, Anastasia
AU - Novikov, Mikhail S.
PY - 2021
DA - 2021/01/01
PB - Acta Naturae Ltd
SP - 78-81
IS - 4
VL - 13
PMID - 35127150
SN - 2075-8251
SN - 2075-8243
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2021_Kozlovskaya,
author = {Elena S Matyugina and Liubov I. Kozlovskaya and Victor P Volok and Elena Y Shustova and Aidar A Ishmukhametov and Sergey N. Kochetkov and Anastasia Khandazhinskaya and Mikhail S. Novikov},
title = {Evaluation of the Antiviral Potential of Modified Heterocyclic Base and 5’-Norcarbocyclic Nucleoside Analogs Against SARS-CoV-2},
journal = {Acta Naturae},
year = {2021},
volume = {13},
publisher = {Acta Naturae Ltd},
month = {jan},
url = {https://doi.org/10.32607/actanaturae.11479},
number = {4},
pages = {78--81},
doi = {10.32607/actanaturae.11479}
}
Cite this
MLA
Copy
Kozlovskaya, Liubov I., et al. “Evaluation of the Antiviral Potential of Modified Heterocyclic Base and 5’-Norcarbocyclic Nucleoside Analogs Against SARS-CoV-2.” Acta Naturae, vol. 13, no. 4, Jan. 2021, pp. 78-81. https://doi.org/10.32607/actanaturae.11479.